Position in EXEL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$278,470
+$23,275 QoQ
Shares Held
5,118
-14.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#529
of 751 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 93%
Shared 0%
None 7%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Aptus Capital Advisors, LLC holds $18,372,145 across 17 Biotechnology names. EXEL ranks #8 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,787 | $6,848,416 | |
| 2 | OCUL |
Ocular Therapeutix, Inc
|
638,691 | $6,271,945 | |
| 3 | RPRX |
Royalty Pharma plc
|
24,206 | $1,357,230 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,389 | $1,020,190 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,180 | $735,777 | |
| 6 | MIST |
Milestone Pharmaceuticals Inc.
|
339,450 | $454,863 | |
| 7 | INCY |
Incyte Corp
|
2,549 | $288,954 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
5,118 | $278,470 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $278,470 | 5,118 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $255,195 | 5,950 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $277,575 | 6,333 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||